Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06071871
Other study ID # UCL/150862
Secondary ID 2022-003727-17
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date April 30, 2024
Est. completion date July 31, 2028

Study information

Verified date March 2024
Source University College, London
Contact PORTAL Trial Manager
Phone 020 7679 9860
Email ctc.portal@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.


Description:

This is a phase 2, open label trial conducted in 2 parts. The overall aim is: Part 1: To determine the efficacy of Pola-Glofit as bridging treatment to CAR-T cell therapy in patients with relapsed or refractory large B cell lymphomas. Part 2: To determine the efficacy of Pola-Glofit in patients with relapsed or refractory large B cell lymphomas who have failed to achieve CMR, or progressed after CAR-T cell therapy. Treatment consists of: Part 1: Patients will receive 2 cycles of Pola-Glofit. Obinutuzumab is given 7 days before the first dose of Glofit. After 2 cycles, patients have a PET-CT scan to check the response. If the scan shows a response and the patient is still suitable for CAR-T, patients will receive planned CAR-T therapy. If the patient is not suitable to continue with CAR-T, patients can receive up to 4 more cycles of Pola-Glofit, and then 6 cycles of Glofit. Part 2: Patients will receive 6 cycles of Pola-Glofit, and then 6 cycles of Glofit. Obinutuzumab is given 7 days before the first dose of Glofit. For both Part 1 and Part 2, all cycles are 21 days. A step-up dosing regimen will be followed: - Cycle 1 Day 1: Obinutuzumab is given intravenously at a dose of 1g over 4-5 hours. - Cycle 1 Day 2: Polatuzumab is given intravenously at a dose of 1.8mg/kg over 90 minutes. - Cycle 1 Day 8: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours. Patients need to stay in hospital for 24 hours. - Cycle 1 Day 15: Glofitamab is given intravenously at a dose of 10mg over 2 hours. (Patients may need to stay in hospital for 24 hours.) - From Cycle 2-6, Polatuzumab is given intravenously at a dose of 1.8mg/kg over 30 minutes on Day 1, and Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1. - From Cycle 7-12, Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1. Patients will be followed up until the last patient completes their 1 year post-treatment follow up visit.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 99
Est. completion date July 31, 2028
Est. primary completion date January 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven CD20+ LBCL (with CD20 positivity at any timepoint) including diffuse large B cell lymphoma, high grade B cell lymphoma with MYC, BCL2 and/or BCL6 (double/triple hit lymphoma), high grade B cell lymphoma not otherwise specified (NOS), primary mediastinal B-cell lymphoma or transformed follicular lymphoma. - Part 1: Relapsed or refractory disease and eligible for CAR T-cell therapy in the UK and in need of systemic bridging in the opinion of the local investigator. - Part 2: Failed to achieve CMR (Deauville score 1-3) on PET scan 1-month post CAR-T or progressed at any point post CAR-T (patients in part 2 may have been previously enrolled in Part 1 and responded to Pola-Glofit bridging or be de novo patients who are naïve to this combination) - At least one measurable target lesion - Patient has recent archival biopsy tissue available or is willing to undergo a new biopsy. - ECOG performance status: - Part 1: ECOG PS 0/1 - Part 2: ECOG PS 0-2 - Life expectancy of = 12 weeks - Adequate haematological status. - Adequate liver and renal function - Negative test for hepatitis B, hepatitis C, HIV and SARS-CoV-2 Exclusion Criteria: - Patients with known active infection - Current = Grade 2 peripheral neuropathy - History of confirmed progressive multifocal leukoencephalopathy - Current evidence of CNS lymphoma - Patients with another invasive malignancy in the last 2 years - Significant history of cardiovascular disease - Active autoimmune disease or immune deficiency - Severe neurological disorder - Uncontrolled tumour-related pain - Uncontrolled pleural effusion, pericardial effusion, or ascites - Treatment with other standard anti-cancer radiotherapy/chemotherapy including investigational therapy and targeted therapy within 4 weeks prior to cycle 1 day 1 - Prior solid organ transplantation - Prior allogeneic stem cell transplant - Autologous SCT within 100 days prior to cycle 1 day 1 - Any history of immune related = Grade 3 adverse events - Ongoing corticosteroid use > 25 mg/day of prednisone or equivalent within 4 weeks prior to study treatment - Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment - Administration of a live, attenuated vaccine within 4 weeks prior to cycle 1 day 1 - History of severe allergic anaphylactic reactions to chimeric or humanised monoclonal antibodies or recombinant antibody-related fusion proteins. - Known hypersensitivity to Chinese hamster ovary cell products or to any component of the obinutuzumab, polatuzumab vedotin and/or glofitamab formulation. - Known or suspected history of HLH

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Glofitamab
Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours. Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant).
Polatuzumab vedotin
Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
Obinutuzumab
Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University College, London Hoffmann-La Roche

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Overall Response Rate (ORR) to Pola-Glofit as bridging prior to CAR-T cell infusion To determine the efficacy of Pola-Glofit as bridging treatment to CAR-T cell therapy in patients with r/r LBCL.
ORR i.e. the proportion of patients achieving response (Complete Metabolic Response or Partial Metabolic Response) after Pola-Glofit bridging but prior to CAR-T cell infusion, assessed by central review as per 2014 Lugano Classification. This will be presented as a rate with a 70% confidence interval.
At Cycle 2 Day 14-19 (or earlier) (each cycle is 21 days)
Primary Part 2: Progression Free Survival (PFS) at 6 months To determine the efficacy of Pola-Glofit in patients with LBCL who have failed to achieve CMR, or progressed after CAR-T cell therapy.
PFS at 6 months will be analysed using Kaplan-Meier survival analysis, with the rate at 6 months (with 70% CI) presented. The median (if reached) and plot will also be given.
From the date of registration at Part 2 until the date of first disease progression or death, whichever comes first, assessed up to 4 years
Secondary Part 1: Complete Metabolic Response (CMR) rate to Pola-Glofit as bridging prior to CAR-T cell infusion Per Lugano 2014 criteria At Cycle 2 Day 14-19 of bridging treatment (each cycle is 21 days)
Secondary Part 1: Overall Survival (OS) and Progression Free Survival (PFS) Medians (if reached), rates at 6 months and 1 year and plots will be presented From the date of registration at Part 1 until the date of disease progression or death (PFS), or death (OS). This will be assessed from the date of registration until up to 4 years.
Secondary Part 1: Safety and toxicity of Pola-Glofit as bridging therapy Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events. Assessed in all patients given at least one dose of study treatment in part 1. From registration and during Part 1 bridging treatment, until end of post-treatment safety reporting window (up to six months after last dose of obinutuzumab, plus a further 35 days after last dose of polatuzumab vedotin or last dose of glofitamab)
Secondary Part 1: CAR-T associated toxicity post Pola-Glofit bridging following CAR-T therapy Assessed in all patients given at least one dose of study treatment in part 1 and infused. Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events. Between Day 0 and Day 28 following CAR-T therapy
Secondary Part 1: Response rate post CAR-T for all infused patients Per Lugano 2014 criteria. Response rates at 1, 3 and 6 months post CAR-T therapy. From CAR-T infusion until 6 months post CAR-T therapy
Secondary Part 1: Duration of Response (DoR) and Duration of Complete Response (DoCR) for Pola-Glofit and CAR-T Response defined as PR (partial response) or better. From the date of first response until disease progression. This will be assessed from the date of registration until up to 4 years.
Secondary Part 1: Non-Relapse Mortality (NRM) NRM rates at 6 months and 1 year From the date of registration until the date of NRM. This will be assessed from the date of registration until up to 4 years.
Secondary Part 2: Complete Metabolic Response (CMR) rate to Pola-Glofit/Glofitamab at any point Per Lugano 2014 criteria From the date of registration until up to 4 years
Secondary Part 2: Response rate for patients who received Pola-Glofit bridging versus those who have not Per Lugano 2014 criteria. Response rates following 2 and 5 cycles of Part 2 treatment. From the date of registration until Cycle 5 (approximately 12 weeks. Each cycle is 21 days).
Secondary Part 2: Safety and toxicity of Pola-Glofit post CAR-T therapy Assessed by CTCAE criteria v5 and ASTCT 2019 criteria for CRS/ICANS adverse events. Assessed in all patients given at least one dose of study treatment in part 2. Throughout Part 2 treatment until end of post-treatment safety reporting window (up to six months after last dose of obinutuzumab, plus a further 35 days after last dose of polatuzumab vedotin or last dose of glofitamab)
Secondary Part 2: Overall Survival (OS) Median (if reached), rates at 6 months and 1 year (with 95% CIs) and plots will be presented. From the date of registration for Part 2 until the date of death, assessed up to 4 years.
Secondary Part 2: Duration of Response (DoR) Response defined as PMR (partial metabolic response) or better. From the date of first response until disease progression, assessed up to 4 years.
Secondary Part 2: Duration of Complete Response (DoCR) From the date of first complete metabolic response (CMR) until disease progression, assessed up to 4 years.
Secondary Part 2: Non-Relapse Mortality (NRM) NRM rates will be presented at 6 months and 1 year. NRM will be measured from the date of registration until the date of NRM. This will be assessed from the date of registration until up to 4 years. NRM rates will be presented at 6 months and 1 year.
Secondary Part 2: Progression Free Survival (PFS) (at 12 months) Median (if reached), rate at 12 months (with 95% CI) and plot will be presented PSF will be measured from the date of registration at Part 2 until the date of disease progression. This will be assessed from the date of registration until up to 4 years. The median rate at 12 months will be presented.
See also
  Status Clinical Trial Phase
Withdrawn NCT05929716 - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT05464719 - A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Phase 2
Recruiting NCT06047080 - An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Phase 3
Active, not recruiting NCT04566978 - 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) Early Phase 1
Recruiting NCT06104592 - Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Phase 2
Recruiting NCT04889716 - CAR-T Followed by Bispecific Antibodies Phase 2
Recruiting NCT04250324 - Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma Phase 1
Recruiting NCT05326243 - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT05794958 - Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Phase 1
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) Phase 1
Recruiting NCT05404048 - PD-L1 PET-imaging During CAR T-cell Therapy Phase 2
Recruiting NCT06375733 - A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL Phase 1/Phase 2
Recruiting NCT05887167 - Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Phase 1
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Recruiting NCT05643742 - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Phase 1/Phase 2
Recruiting NCT05820841 - Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma Phase 3
Recruiting NCT05472610 - Study of Efficacy of BZ019 in Large B-cell Lymphoma Phase 2
Recruiting NCT03960840 - Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL Phase 1/Phase 2
Recruiting NCT06356129 - Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Phase 3
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1